Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Novartis’s Lucentis Captures Two-Thirds of Wet AMD Patient Share in Europe Driven by Strong First-Line Preference among



  Novartis’s Lucentis Captures Two-Thirds of Wet AMD Patient Share in Europe
  Driven by Strong First-Line Preference among Retinal Specialists, According
  to a Recent BioTrends Report

Business Wire

EXTON, Penn. -- November 26, 2012

BioTrends Research Group, one of the world’s leading research and advisory
firms for specialized biopharmaceutical issues, finds that retinal specialists
in the EU5 (France, Germany, Italy, Spain and the UK) treat 66 percent of
intravitreal-pharmaceutically-treated wet age-related macular degeneration
(AMD) patients with Novartis’s Lucentis and 27 percent of patients with
Genentech / Roche’s Avastin. TreatmentTrends^®: Age-Related Macular
Degeneration in the EU  also finds that three-quarters of surveyed retinal
specialists consider Lucentis to be their preferred first-line therapy for wet
AMD, with prescribing being driven by high overall satisfaction with the agent
and positive perceptions across efficacy-, safety-, tolerability-,
convenience- and company support-related attributes. In contrast to this
preference for Lucentis in the EU5, data published in the recent parallel U.S.
report finds that, although not FDA approved for the treatment of wet AMD,
Avastin is the intravitreal pharmacotherapy with the strongest first-line
preference and greatest wet AMD patient share (63 percent), with Lucentis
capturing 23 percent patient share.

Given the positive recommendation by the Committee for Medicinal Products for
Human Use (CHMP) for the approval of Bayer’s aflibercept (VEGF Trap-Eye) for
the treatment of wet AMD during study fielding, it is interesting to note that
69 percent of retinal specialists who report unaided awareness of products in
development for wet AMD specifically mention aflibercept. Furthermore, 85
percent of retinal specialists report aided awareness of aflibercept,
significantly more than those aware of other surveyed products in development
for wet AMD, including Ophthotech’s Fovista, GlaxoSmithKline’s pazopanib and
Ohr Pharmaceutical’s squalamine. This relatively higher awareness around
aflibercept is likely due to the fact that aflibercept has been commercially
available in the U.S. since 2011, where it is marketed by Regeneron as Eylea^®
for the treatment of wet AMD. Assuming commercial availability of aflibercept
in the current market, retinal specialists consider 42 percent of their
current wet AMD patients to be likely candidates for the product, with the
greatest percent of potential patients being either treatment-naïve or
switched from Lucentis. Indeed, retinal specialists anticipate administering
aflibercept to ten percent of their intravitreal-pharmaceutically-treated wet
AMD patients over the next six months, pulling directly from Lucentis patient
share, which is expected to contract significantly.

TreatmentTrends^®: AMD in the EU is an annual syndicated primary market
research report series that provides a comprehensive view of the current and
expected future management of AMD, with a focus on wet AMD, in the EU5. The
survey was fielded in September and October 2012 with 220+ retinal
specialists. A parallel report covering the US market is also available. These
reports cover the use of treatment approaches and pharmacotherapy agents for
the treatment of dry and wet AMD, as well as attitudes and perceptions toward
these products, advantages and disadvantages, ideal patient types, barriers to
growth, and expected future use. In addition, respondents were queried about
their awareness of and interest in products in development for the treatment
of dry AMD or wet AMD. An additional series of pre-launch questions were also
included to assess the potential market opportunity for aflibercept.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or
www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
at www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.

Contact:

BioTrends Research Group
Emma Williams, 610-321-9441
ewilliams@bio-trends.com
or
Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement